Ige Mediated
Ige Mediated - Related Videos
10:22
Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
0 Views •
Cited by 14 •
2011
Basophil activation test is a potent tool for the detection of IgE-dependent allergies in vitro. Here, an optimized protocol for basophil activation test is used to investigate drug hypersensitivity. A method for the efficient production of covalent drug-protein conjugates and their physicochemical characterization is described.
09:40
Detection of True IgE-expressing Mouse B Lineage Cells
0 Views •
Cited by 3 •
2014
In vitro analysis of class switch recombination in mice is challenging due to cytophilic IgE molecules bound to Fc receptors on the surface of B cells. We describe a method for IgE detection using trypsin-mediated cleavage of surface-bound IgE prior to fixation and permeabilization for cytoplasmic fluorescence staining.
05:39
Humanized Mediator Enzyme Release Assay: An Immunochemical Method to Screen Allergic Potential of Test Antigen by Monitoring Basophil Degranulation Response In Vitro
0 Views •
2025
In this video, we describe an in vitro method to evaluate the allergic potential of an antigen to induce basophil degranulation. β-hexosaminidase is used as an index of chemical mediator release, and the enzyme activity of β-hexosaminidase is measured using a fluorogenic substrate.
01:25
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
0 Views •
2024
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed. Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
07:31
Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcεRI
0 Views •
Cited by 16 •
2014
The current study describes the development and applications of a genetically engineered assay system based on the transfection of rat basophilic leukemia cells with the equine FcεRIα gene. Transfected cells express a functional receptor where the release of mediators of the allergic response can be activated by IgE and antigen.
FAQs
Cross-linking brings adjacent IgE molecules together when an allergen binds them, activating the high-affinity FcεRI receptors on mast cells and basophils. This receptor signal initiates degranulation, allowing these cells to release inflammatory mediators rapidly. The mechanism explains why exposure after sensitization can produce a quick clinical response rather than a delayed, nonspecific inflammatory reaction.
Histamine, leukotrienes, and other released substances contribute to different aspects of the response, including itching, wheezing, and urticaria. Their immediate effects account for rapid symptoms, whereas later inflammatory signaling can extend tissue involvement after the initial cellular activation. Recognizing both phases helps clinicians interpret why symptoms may persist beyond the first exposure response.
FcεRI provides the mast cell and basophil surface with a high-affinity site for IgE, positioning antibody-bound allergen recognition close to the machinery that triggers mediator release. Because activation occurs through this receptor-linked arrangement, it is central to understanding IgE-dependent inflammation. The pathway also identifies receptor activation as a potential point for treatments intended to interrupt the response.
Clinical evaluation can incorporate allergy testing to assess whether a suspected reaction is associated with IgE-dependent sensitization. The findings contribute to diagnosis and help place symptoms within a broader risk assessment rather than serving as an isolated description of inflammation. This information can guide clinical care when rapid symptoms such as itching, wheezing, or urticaria follow allergen exposure.
Management approaches may focus on reducing mediator release or interrupting IgE-dependent cellular activation. These strategies address the pathway upstream of the symptoms produced by histamine, leukotrienes, and related substances. Linking treatment goals to the underlying mechanism helps clinicians select care aimed not only at relieving manifestations but also at limiting the inflammatory process that sustains them.
IgE-mediated activation can affect mast cells and basophils and generate a rapid release of inflammatory mediators. Because the resulting response may include wheezing, urticaria, or anaphylaxis, identifying this pathway is relevant to clinical risk assessment. Its importance extends beyond routine allergy diagnosis: understanding the mechanism helps connect the timing and severity of symptoms with appropriate clinical attention.